Gyre Therapeutics (GYRE) said Monday that China's National Medical Products Administration approved its application to conduct a clinical trial evaluating pirfenidone capsules for radiation-induced lung injury, with or without immune-related pneumonitis.
The company said it expects to start the phase 2/3 trial to assess dosing and efficacy in H2 2025 at oncology and academic centers in China.
Shares of the company were down 1.8% in recent Monday trading.
Price: 8.95, Change: -0.16, Percent Change: -1.76
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.